FDA to assess Merck's intravenous anti-infective drug

11/18/2013 | eMPR.com

The FDA will conduct a priority review of Merck & Co.'s new drug application for an intravenous solution of posaconazole, an antifungal drug. The oral solution of posaconazole was approved to prevent Aspergillus and Candida infections in immunocompromised patients who underwent stem cell transplants and developed graft-versus-host disease and those with neutropenia caused by chemotherapy.

View Full Article in:

eMPR.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC